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Abstract
Anti-CD20 antibody treatments, such as obinutuzumab, have been associated with infusion-related reactions (IRRs). In the phase
3 iLLUMINATE study of ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab in first-line chronic lymphocytic
leukemia/small lymphocytic lymphoma, IRRs were substantially reduced with ibrutinib-obinutuzumab versus chlorambucil-
obinutuzumab. We prospectively analyzed inflammatory cytokines to evaluate the impact of ibrutinib on circulating cytokine
levels following obinutuzumab infusion. In iLLUMINATE, ibrutinib or chlorambucil was given approximately 30–120 min
before the first obinutuzumab infusion. Cytokines evaluated were IFNγ, IL-6, IL-8, IL-10, IL-18,MCP-1, MIP-1α, MIP-1β, and
TNFα. Changes in peak cytokine levels from baseline (immediately before obinutuzumab) to post-obinutuzumab infusion were
compared between arms and between patients with versus without IRRs using Wilcoxon rank sum test. Of 228 treated patients,
95 on ibrutinib-obinutuzumab (15 with IRRs, 80 without) and 88 on chlorambucil-obinutuzumab (45 with IRRs, 43 without)
with cytokine data were included. Irrespective of IRR occurrence, median increase in cytokines was lower with ibrutinib-
obinutuzumab versus chlorambucil-obinutuzumab for all cytokines (P < 0.01) except MIP-1β. Across treatment arms, post-
obinutuzumabmedian increase in all cytokines exceptMIP-1βwas greater in patients with versus without IRRs (P < 0.001). IL-6
and IL-8 elevations were associated with IRRs in both treatment arms. Among patients with IRRs, those receiving ibrutinib-
obinutuzumab had lower post-obinutuzumab increases in IL-6, IL-8, IL-10, and MCP-1 (P < 0.04) than patients receiving
chlorambucil-obinutuzumab. For patients in the ibrutinib-treatment arm, we observed a reduction in both the rate of clinically
apparent IRRs and the levels of IRR-related cytokines and chemokines. This observation supports an immunomodulatory
mechanism of action for ibrutinib. Clinical Trial Registration: NCT02264574
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Introduction
Established therapies for the first-line treatment of chronic
lymphocytic leukemia (CLL) include novel targeted agents,
such as ibrutinib, and chemoimmunotherapy regimens.
Typically, chemoimmunotherapy regimens contain anti-
CD20 monoclonal antibodies (mAbs), such as rituximab or
obinutuzumab. Anti-CD20 mAbs have demonstrated efficacy
when used alone or in combination for patients with previous-
ly untreated and relapsed/refractory CLL [1–3], with greater
efficacy observed for obinutuzumab compared with rituximab
when combined with chlorambucil in first-line CLL [3].
Ibrutinib is the only once-daily oral inhibitor of Bruton’s ty-
rosine kinase (BTK) approved for treatment of CLL in the
United States and European Union that has demonstrated sig-
nificant progression-free survival (PFS) and overall survival
(OS) benefit versus established therapies (including
chemoimmunotherapy regimens) in randomized phase 3 stud-
ies in first-line CLL/small lymphocytic lymphoma (SLL) [2,
4, 5].
Despite their efficacy, the administration of mAbs can re-
sult in adverse events including infusion-related reactions
(IRRs). IRRs are potentially serious complications that occur
rapidly post-infusion and arise from an immune-mediated re-
action to the infusion of a drug, notably including mAbs [6].
The severity of IRRs ranges frommild reactions involving flu-
like symptoms to rare fatal events.
The rate and severity of IRRs vary depending on the spe-
cific treatment. For instance, obinutuzumab is generally asso-
ciated with more frequent and more severe IRRs than rituxi-
mab as observed in the CLL11 study of patients with previ-
ously untreated CLL (any grade: 66% versus 38%; grade ≥ 3:
20% versus 4%, respectively) [3] and in the GALLIUM study
of patients with follicular lymphoma (any grade: 68% versus
59%; grade ≥ 3: 12% versus 7%, respectively) [3, 7]. A study
of patients with relapsed/refractory non-Hodgkin lymphoma
who were treated with obinutuzumab resulted in a similar rate
of IRRs (any grade: 69%; grade ≥ 3: 11%) [8]. It has been
hypothesized that the structure of obinutuzumab (a type II,
glycoengineered, humanized mAb) induces greater cellular
activation, thereby eliciting the increase in IRRs seen in these
studies [9].
In the phase 3 iLLUMINATE (PCYC-1130) study that
compared f i rs t - l ine ibrut in ib-obinutuzumab and
chlorambucil-obinutuzumab in patients with previously un-
treated CLL, ibrutinib-obinutuzumab demonstrated superior
PFS including in patients with one or more high-risk genomic
features (del[17p]/TP53mutation, del[11q], and/or unmutated
IGHV) [1]. Of note, the rate of IRRs in iLLUMINATE was
lower in patients treated with ibrutinib-obinutuzumab
compared with those treated with chlorambucil-
obinutuzumab (any grade: 25% versus 58%; grade ≥ 3 or
serious: 3% versus 9%, respectively) [1]. This finding sup-
ported the notion that the administration of ibrutinib prior to
obinutuzumab infusion reduced the risk of IRRs. To investi-
gate the role of ibrutinib in IRRs, we prospectively analyzed
patient samples from iLLUMINATE for circulating cytokines
and chemokines thought to be associated with IRRs.
Methods
Study design and population
iLLUMINATE (PCYC-1130; NCT02264574) is a phase 3,
international, randomized open-label study of ibrutinib plus
obinutuzumab versus chlorambucil plus obinutuzumab in
first-line CLL/SLL. Eligible patients were aged ≥ 18 years
with previously untreated, active CLL/SLL and were aged ≥
65 years or < 65 years with coexisting conditions (Cumulative
Illness Rating Scale score > 6, creatinine clearance < 70 mL/
min, presence of del(17p) by fluorescent in situ hybridization,
or TP53 mutation). Informed consent was obtained from all
participants included in the study. The study design has been
previously described [1].
Procedures
Patients were randomly assigned (1:1) to receive
ibrutinib-obinutuzumab or chlorambucil-obinutuzumab.
In the ibrutinib-obinutuzumab arm, patients received
420-mg ibrutinib once daily until progressive disease or
unacceptable toxicity in combination with obinutuzumab
(100 mg on day 1, 900 mg on day 2, 1000 mg on days 8
and 15 of cycle 1, and then 1000 mg on day 1 of each
subsequent 28-day cycle for a total of 6 cycles). In the
chlorambucil-obinutuzumab arm, patients received 0.5-
mg/kg chlorambucil on days 1 and 15 of each 28-day
cycle for 6 cycles with obinutuzumab, as above (total of
6 cycles).
All patients received the same, standard prophylactic med-
ications for obinutuzumab-related IRRs that included intrave-
nous corticosteroids, oral analgesics/antipyretics, and an anti-
histamine. Based on the hypothesis that ibrutinib might reduce
the incidence of IRRs, the oral study drug (ibrutinib or
chlorambucil) was administered approximately 30 to
120 min before the first obinutuzumab infusion.
Plasma samples were collected at 4 time points on day
1: before the ibrutinib/chlorambucil dose (Online
Resource Table S1), immediately prior to infusion of
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obinutuzumab, and 2 and 4 h into the obinutuzumab in-
fusion. Baseline was defined as immediately before
obinutuzumab infusion rather than prior to ibrutinib/
chlorambucil treatment, as there were no meaningful dif-
ferences between the two time points (Online Resource
Table S2). Cytokines and chemokines that were evaluated
included interferon-γ (IFNγ), interleukin (IL)-6, IL-8/
CXCL8, IL-10, IL-18, monocyte chemoattractant
protein-1 (MCP-1)/CCL2, macrophage inflammatory pro-
tein (MIP)-1α/CCL3, MIP-1β/CCL4, and tumor necrosis
factor-α (TNFα). A multi-analyte immunoassay panel
(Myriad RBM, Austin, Texas, USA) was used to analyze
the level of plasma cytokines and chemokines.
Statistical analysis
Changes from baseline to post-obinutuzumab infusion peak
cytokine/chemokine levels were compared between arms, as
well as between patients with and without IRRs, using
Wilcoxon rank sum test. A 2-sided P value of < 0.05 was
considered significant with no adjustments for multiplicity.
Analysis of covariance (ANCOVA) was performed to
evaluate each of the baseline factors associated with increase
in post-obinutuzumab cytokine levels (log-adjusted) with
baseline of the cytokine level as a covariate in the model:
sex (male versus female), bulky disease (lymph nodes <
5 cm versus ≥ 5 cm), Rai stage (stage III/IV versus others),
splenomegaly (yes/no), age (continuous variable), and log-
transformed hematologic parameters (hemoglobin, platelet
counts, absolute neutrophil count, and absolute lymphocyte
count, all as continuous variables).
Multivariable logistic regression was performed to
identify predictors of IRRs. Explanatory variables were
first selected based on a univariate logistic regression
model at a P < 0.2 level among the following factors:
treatment arm, baseline clinical factors (stated above),
and log-transformed baseline cytokine levels (IFNγ, IL-
6, IL-8, IL-10, IL-18, TNFα, MCP-1, MIP-1α, and MIP-
1β). Correlation between selected factors was also exam-
ined. Independent variables (absolute value of Pearson
correlation coefficient < 0.2) were included in the multi-
variable model. If any pair of the variables correlated,
only the variable with the smaller P value in the univar-
iate model was entered into the multivariable model.
Data sharing statement
Requests for access to individual participant data from clinical
studies conducted by Pharmacyclics LLC, an AbbVie
Company, can be submitted through the Yale Open Data
Access (YODA) Project site at http://yoda.yale.edu.
Results
Analysis population and patient characteristics
Of 228 treated patients, 95 of 113 patients (84%) in the
ibrutinib-obinutuzumab arm and 88 of 115 patients (77%)
in the chlorambucil-obinutuzumab arm had cytokine/
chemokine results and were included in the cytokine/
chemokine analysis population. In the ibrutinib-
obinutuzumab arm (n = 95), 15 patients (16%) had any
grade IRRs on day 1, and 80 patients (84%) did not ex-
perience IRRs. In the chlorambucil-obinutuzumab arm (n
= 88), 45 patients (51%) had any grade IRRs on day 1,
and 43 patients (49%) did not experience IRRs.
Baseline characteristics were generally similar between
treatment arms in the analysis population (Table 1).
Numerically lower platelet counts were observed in the
ibru t in ib-obinutuzumab arm compared wi th the
chlorambucil-obinutuzumab arm (median, 150 × 109/L versus
162 × 109/L, P = 0.0413), which was not a clinically relevant
difference. Baseline MCP-1 levels were also significantly
lower in the ibrutinib-obinutuzumab arm compared with the
chlorambucil-obinutuzumab arm (median, 127 pg/mL versus
191.5 pg/mL, P = 0.0089), though both of these values fall
within a normal range [10, 11]. Additionally, since a similar
arm difference was observed prior to administration of any
study drug (Online Resource Table S1), this indicates that
the difference was due to the chance of randomization and
was not related to any study treatment. Patients in both arms
had median baseline levels of IFNγ and IL-6 that were below
the detectable threshold of the assay (Table 1), which preclud-
ed their inclusion in the analysis as a predictor for the devel-
opment of IRRs.
Analysis of change in cytokine levels by treatment
arm and IRR status
Overall, increases over baseline levels were observed post-
obinutuzumab infusion across all cytokines and chemokines
analyzed regardless of treatment arm or IRR occurrence.
Median change from baseline levels was significantly lower
(P < 0.01) in patients treated with ibrutinib-obinutuzumab
compared with chlorambucil-obinutuzumab for IFNγ, IL-6,
IL-18, IL-8, IL-10, TNFα, MCP-1, and MIP-1α (Fig. 1).
MIP-1β was the only chemokine for which the change from
baseline levels was not significantly different between treat-
ment arms (P = 0.7747).
Across both treatment arms, increases in median changes
from baseline levels were significantly greater (P < 0.001) for
patients with IRRs (n = 60) compared with patients without
IRRs (n = 123) for all cytokines and chemokines analyzed
except for MIP-1β (P = 0.6290) (Fig. 2, Online Resource
Fig. S1).
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Analysis of cytokine/chemokine patterns in patients within
each treatment arm showed that greater increases from base-
line levels in IL-6 and IL-8 post-obinutuzumab were signifi-
cantly associated with IRRs in both ibrutinib-obinutuzumab
(P = 0.0012 and P = 0.0126, respectively) and chlorambucil-
obinutuzumab treated patients (P = 0.0097 and P = 0.0234,
respectively). In the ibrutinib-obinutuzumab arm, patients
with IRRs also had significantly greater increases in post-
obinutuzumab levels of IL-18, TNFα, MCP-1, and MIP-1α
(P < 0.04) (Fig. 3) than patients without IRRs. In the
chlorambucil-obinutuzumab arm, patients with IRRs also
had greater increases than patients without IRRs in post-
obinutuzumab levels of IFNγ and IL-10 (P < 0.03) (Fig. 3).
ANCOVA was performed to evaluate potential baseline
characteristics associated with the increase in absolute values
from baseline of cytokine and chemokine levels observed
Table 1 Patient demographics








Median age, years (range) 70 (47–87) 72 (40–86)
Male, n (%) 60 (63) 63 (72)
Rai stage III/IV, n (%) 49 (52) 45 (51)
Bulky disease ≥ 5 cm, n (%) 25 (26) 33 (38)
Splenomegaly, n (%) 80 (84) 74 (84)
Median hemoglobin, g/dL (range) 115 (58–163) 112 (72–153)
Median platelet counts, × 109/L (range) 150 (48–359) 162 (48–463)
Median absolute neutrophil count, × 109/L (range) 6 (0–362) 5 (0–61)
Median absolute lymphocyte count, × 109/L (range) 54 (1–350) 48 (1–386)
Median baseline cytokine levels, pg/mL (range)
IFNγ < 6.8 (NA) < 6.8 (NA)
IL-6 < 3.4 (NA–957) < 3.4 (NA–252)
IL-8 6.6 (6.0–750) 9.0 (6.0–306)
IL-10 9.0 (5.2–1090) 11.0 (5.2–155)
IL-18 416.0 (69–5540) 401.0 (117–3010)
MCP-1 127.0 (110–1920) 191.5 (110–3090)
MIP-1α 34.0 (25–4070) 30.0 (25–741)
MIP-1β 384.0 (45–44400) 446.0 (45–5920)
TNFα 26.0 (18–887) 24.5 (18–335)
a Enrolled in iLLUMINATE, n = 113
b Enrolled in iLLUMINATE, n = 116
IFN, interferon; IL, interleukin; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory pro-
tein; NA, not available (below the lower limit of detection); TNF, tumor necrosis factor
Fig. 1 Median changes in cytokine and chemokine levels from baseline
to post-obinutuzumab peak by treatment arm. Median changes over
baseline (i.e., immediately before obinutuzumab) are shown for all
cytokines and chemokines examined by treatment arm. IFN, interferon;
IL, interleukin; MCP, monocyte chemoattractant protein; MIP,
macrophage inflammatory protein; TNF, tumor necrosis factor
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post-obinutuzumab infusion in each treatment arm. In the
ibrutinib-obinutuzumab arm, factors associated with an in-
crease in cytokine and chemokine levels included splenomeg-
aly (IL-6, IL-8, MCP-1, MIP-1α, TNFα), lower hemoglobin
levels (IL-8), higher absolute neutrophil count (IL-8, MCP-1,
MIP-1α, TNFα), and higher absolute lymphocyte count
(IFNγ, IL-6, IL-8, MCP-1, MIP-1α, TNFα). In the
chlorambucil-obinutuzumab arm, factors associated with an
increase in cytokine and chemokine levels included Rai stage
III/IV (IL-8, IL-18), bulky disease (≥ 5 cm: IL-10, TNFα),
splenomegaly (IFNγ, IL-18, IL-6, IL-8, MIP-1α, TNFα),
lower hemoglobin levels (IL-10, IL-8), lower platelet count
(IL-18, MCP-1, MIP-1β), and higher absolute lymphocyte
count (IFNγ, IL-10, IL-6, IL-8, MCP-1, MIP-1α, TNFα)
(Online Resource Table S3).
In patients with IRRs and comparing between treatment
arms, patients treated with ibrutinib-obinutuzumab had lower
increases over baseline in IL-6, IL-8, IL-10, and MCP-1 com-
pared with patients treated with chlorambucil-obinutuzumab
(P < 0.04) (Fig. 4).
Fig. 2 Median changes in cytokine and chemokine levels from baseline
to post-obinutuzumab peak by occurrence of IRR on day 1. Median
changes over baseline (i.e., immediately before obinutuzumab) are
shown for all cytokines and chemokines examined by all patients and
their IRR status. IFN, interferon; IL, interleukin; IRR, infusion-related
reaction; MCP, monocyte chemoattractant protein; MIP, macrophage
inflammatory protein; TNF, tumor necrosis factor
a
b
Fig. 3 Median changes in cytokine and chemokine levels from baseline
to post-obinutuzumab peak by occurrence of IRR on day 1. Median
changes over baseline (i.e., immediately before obinutuzumab) are
shown for all cytokines and chemokines examined by treatment arm (a
ibrutinib-obinutuzumab; b chlorambucil-obinutuzumab) and IRR
occurrence. IFN, interferon; IL, interleukin; IRR, infusion-related
reaction; MCP, monocyte chemoattractant protein; MIP, macrophage
inflammatory protein; TNF, tumor necrosis factor
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Multivariable analysis of baseline predictors of IRRs
Among all baseline factors, five were selected as explanatory
variables for the multivariable logistic model: treatment arm,
sex, absolute lymphocyte count, IL-18, andMCP-1. IFNγ and
IL-6 had undetectable levels at baseline and could not be in-
cluded in the evaluation of IRR predictors. Two baseline fac-
tors had a significance of P < 0.2 in the univariate model but
were excluded due to correlation: baseline bulky disease cor-
related with baseline absolute lymphocyte count (Pearson cor-
relation coefficient 0.200) and baseline IL-10 correlated with
both baseline IL-18 (Pearson coefficient 0.592) and MCP-1
(Pearson coefficient 0.284). All other baseline factors were
excluded due to P > 0.2 in the univariate analysis. In the final
multivariable model, treatment arm, baseline absolute lym-
phocyte count, and baseline IL-18 were independently asso-
ciated with the likelihood of IRRs (P < 0.05). Within each
arm, the multivariable model demonstrated that baseline IL-
18 was associated with the likelihood of IRRs in the ibrutinib-
obinutuzumab arm, and baseline absolute lymphocyte count
was associated with the likelihood of IRRs in the
chlorambucil-obinutuzumab arm.
Discussion
In iLLUMINATE, the frequency and severity of IRRs were
reduced in patients treated with ibrutinib-obinutuzumab com-
pared with those treated with chlorambucil-obinutuzumab [1].
This decrease in IRRs with ibrutinib-based treatment is con-
sistent with results from the phase 3 iNNOVATE study,
which evaluated ibrutinib combined with rituximab versus
rituximab alone in patients with Waldenström’s macroglobu-
linemia, and showed that any grade and grade ≥ 3 IRRs oc-
curred less frequently with ibrutinib-rituximab versus
placebo-rituximab (any grade: 43% versus 59%; grade ≥ 3:
1% versus 12%, respectively) [12]. In a recent phase 1/2 study
of ibrutinib-obinutuzumab in first-line CLL, Velez Lujan et al.
reported that only 19% of treated patients developed IRR
symptoms (grades 1–2: 15%; grade 3: 3%) [13], which com-
pares favorably with historical rates of IRRs with
obinutuzumab as single-agent or in other (non-ibrutinib) com-
bination regimens (all grades: 65–90%; grade ≥ 3: 2.5–20%)
[3, 14, 15]. Ibrutinib has also been shown to reduce the sever-
ity of cytokine release syndrome (CRS) in recent studies of
patients with relapsed/refractory CLL receiving chimeric an-
tigen receptor-modified T-cell (CAR-T) therapy [16, 17].
Taken together, these studies indicate a role for ibrutinib in
modulating the immune response to certain therapies.
While the mechanism of IRRs is not fully understood,
the development of IRRs has been associated with the
release of proinflammatory cytokines. In the case of the
anti-CD20 mAbs rituximab and obinutuzumab, these pro-
inflammatory cytokines include TNFα, IL-6, and IL-8
[18, 19]. Freeman et al. used multivariable logistic regres-
sion models to determine baseline factors associated with
IRR risk in the CLL11 study and determined that CD20
expression level was a main predictor of IRRs post-
obinutuzumab or rituximab infusion [9]. Additionally, an
absolute lymphocyte count of ≥ 50 × 109/L has been
shown to be a risk factor for IRRs, particularly for severe
IRRs [18].
In a pre-clinical model of CAR-T therapy, the addition
of ibrutinib significantly reduced serum cytokines associ-
ated with CRS including IFNγ, IL-6, TNFα, IL-2, and
GM-CSF [20]. In patients with CLL, treatment with
ibrutinib has been shown to decrease regulatory T cells
and modulate the cytokine and chemokine milieu in vivo
through the decrease of several cytokines (including IL-
10, IFNγ, IL-6, and TNFα) and chemokines (including
IL-8, MCP-1, MIP-1α, and MIP-1β) [21, 22]. We hy-
pothesized that pretreatment with ibrutinib in patients re-
ceiving obinutuzumab infusion led to decreased IRRs be-
cause of the potential modulatory effect of ibrutinib on the
Fig. 4 Median changes in cytokine and chemokine levels from baseline
to post-obinutuzumab peak by treatment arm in patients with IRRs on day
1.Median changes over baseline (i.e., immediately before obinutuzumab)
are shown for all cytokines and chemokines examined by treatment arm
for only patients who experienced an IRR. IFN, interferon; IL,
interleukin; MCP, monocyte chemoattractant protein; MIP, macrophage
inflammatory protein; TNF, tumor necrosis factor
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release of proinflammatory cytokines. In iLLUMINATE,
serial measurements of plasma-based inflammatory
markers were prospectively performed for various cyto-
kines and chemokines known to be associated with IRRs
and anti-CD20 therapy (Online Resource Table S4).
In our analysis, significant increases in post-obinutuzumab
levels of IL-6 and IL-8 were observed across both treatment
arms in patients with IRRs versus patients who did not expe-
rience IRRs. This finding is consistent with prior reports of
obinutuzumab-induced IRRs associated with IL-6 and IL-8
[9]. While the post-infusion increase in IL-6 and IL-8 levels
among patients with IRRs was common to the 2 arms, the
patterns of other cytokine and chemokine levels released
post-obinutuzumab differed.
Within the ibrutinib-obinutuzumab arm, patients with
IRRs (versus those without IRRs) had significantly higher
levels of IL-6, IL-8, TNFα, IL-18, MCP-1, and MIP-1α,
whereas in the chlorambucil-obinutuzumab arm, patients
with IRRs had significantly higher levels of IFNγ, IL-6,
IL-8, and IL-10 compared with those without IRRs. In a
multivariable analysis of baseline factors associated with
IRRs during ibrutinib-obinutuzumab treatment, only
higher baseline levels of IL-18 predicted the risk of de-
veloping IRRs. For patients in the chlorambucil-
obinutuzumab arm, elevated baseline absolute lymphocyte
counts and MCP-1 were factors independently predictive
of IRR risk. Results from the multivariable analysis are
limited given that some cytokines (particularly IFNγ and
IL-6) had baseline levels that were below the detectable
threshold of the assay, preventing their inclusion in the
multivariable analysis assessing for predictive variables
for IRRs. In addition, the small number of patients who
experienced IRRs within the ibrutinib-obinutuzumab arm
(n = 15) may also limit interpretations of the current
analysis.
These findings differ from a recent report of cytokine anal-
ysis from a phase 1/2 study in 32 patients treated with first-line
ibrutinib-obinutuzumab [13]. In that study, significant in-
creases from baseline in IFNγ, MIP-1α, and TNFα post-
obinutuzumab infusion were observed in patients who devel-
oped IRRs. In univariate analysis, baseline levels of IFNγ, IL-
6, and MIP-1α were found to be significantly higher in pa-
tients who developed IRRs. Differences between findings
from our current analysis and the published phase 1/2 report
with ibrutinib-obinutuzumab may be partially due to patient
population differences in burden of disease, panels of cyto-
kines and chemokines analyzed (iLLUMINATE included
MCP-1), methods of analysis, and sample size (the larger
number of patients in iLLUMINATE allowed multivariable
analysis).
Our analysis shows that patients treated with ibrutinib
versus chlorambucil prior to obinutuzumab infusion had
significantly lower increases from baseline for all
cytokines and chemokines, except MIP-1β. The pattern
of cytokines released during IRRs appeared to differ by
treatment regimen, where significantly lower increases in
post-obinutuzumab cytokine levels were observed with
i b r u t i n i b - ob i nu t u zumab ve r su s ch l o r ambuc i l -
obinutuzumab for IL-6, IL-8, IL-10, and MCP-1.
Increases in IL-6 and IL-8 levels have been shown to be
related to IRRs induced by obinutuzumab [19]. IL-10 is
an anti-inflammatory cytokine that functions to suppress
and dampen immune responses. Increases in IL-10 were
observed in a patient with diffuse large B-cell lymphoma
who experienced a fatal IRR after treatment with rituxi-
mab [23]. MCP-1 is a chemokine that acts as a main
chemoattractant for monocytes and macrophages, and el-
evated levels of MCP-1 were associated with severe cy-
tokine release syndrome in patients with B-cell malignan-
cies treated with chimeric antigen receptor T-cell therapy
[24].
The mechanism by which ibrutinib treatment decreases
or inhibits circulating cytokine and chemokine levels that
contribute to IRRs remains unknown. An in vitro study
showed that rituximab mediated the CD20 trogocytosis of
B cells that led to the rapid production and release of IL-6
[25]. Ibrutinib has been shown to potently inhibit
trogocytosis mediated by anti-CD20 mAbs in CLL cells
in vitro [26]. This inhibition of trogocytosis by ibrutinib
could potentially explain the attenuated release of IL-6
observed in the current analysis; however, further studies
are needed to investigate the exact mechanism. Although
several pre-clinical studies have shown that treatment with
ibrutinib may antagonize the mechanism of anti-CD20
antibodies (particularly as it relates to cell-mediated effec-
tor mechanisms such as antibody-dependent cellular cyto-
toxicity) [27–29], these observations have not translated
to the clinical setting [14, 30–32]. In the recent phase 3
Alliance (A041202) study that evaluated ibrutinib-based
treatment (single-agent ibrutinib or ibrutinib-rituximab
combination) versus bendamustine-rituximab in first-line
CLL, slightly higher responses were observed for
ibrutinib-rituximab than for single-agent ibrutinib (com-
plete response [CR] rate: 12% and 7%; undetectable min-
imal residual disease [MRD] 4% and 1%). There was no
difference, however, in PFS between the two arms (88%
versus 87% at 2 years), although it should be noted the
study was not designed to compare between the two
ibrutinib-based treatment arms [31].
The current analysis demonstrates that ibrutinib sup-
presses obinutuzumab-induced increases in multiple cyto-
kines and chemokines related to IRRs and suggests that
the reduction in IRR events in ibrutinib-treated patients is
the result of a reduction in the release of inflammatory
cytokines and chemokines. These observations may have
implications for immunotherapeutic approaches where the
1739Ann Hematol (2021) 100:1733–1742
tuning of the inflammatory reaction may modify the type
and degree of cytokine release patterns (activated or
dampened) and their role in the treatment effect or safety
profile of immunotherapies.
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